Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.67 USD
+0.01 (0.38%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.67 USD
+0.01 (0.38%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
by Zacks Equity Research
Galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Galectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Company News for Apr 15, 2021
by Zacks Equity Research
Companies in the news are: FRC, TV, GALT, DG
New Strong Sell Stocks for October 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Galectin Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.
Small Drug Stock Outlook: Innovation Holds the Key to Growth
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Buy Stocks for August 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.
Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
by Zacks Equity Research
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Alkermes Sinks as FDA Refuses to Approve Depression Drug
by Zacks Equity Research
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
by Zacks Equity Research
AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.
Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GALT) Outperforming Other Medical Stocks This Year?
Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
by Zacks Equity Research
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
by Zacks Equity Research
Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.